News

This formulation could potentially be a breakthrough in avoiding the fluid retention or hypersensitivity and extravasation reactions which are associated with Taxotere. Initial preclinical studies have shown a

The contract provides funding of up to $30 million, with additional options that may be triggered at the discretion of the National Institutes of Health (NIH) worth a

The companies will be developing GA101, a humanized anti-CD20 monoclonal antibody engineered to increase both direct- and immune-mediated target cell death, for the potential treatment of hematological malignancies

The partnership between the two companies grants SpineSmith the exclusive rights to sell WAVE’s pre-surgical vibration conditioning technology – effectively introducing the approach to the orthopedic and neurological

Under the terms of the agreements with Solvay, York Pharma has acquired Flammazine and Flammacerium, both brands for the prevention and treatment of infections in burn wounds and

Mr Carbonnel is a consultant and corporate financial advisor. He is also chairman of the board of Thomson, an international multimedia corporation. Previously, Mr Carbonnel was a managing

Participants include leading biotechnology investors Index Ventures Growth, Abingworth, Dafna Capital Management, and Merlin Nexus, among others. Certain Micromet board members and affiliated entities also participated in the

The primary objective of the Phase I study is to evaluate the safety and tolerability of PG102. The study design includes evaluation of pharmacodynamic and clinical parameters, to

The international Serve-HF study will focus specifically on the impact of treatment of central sleep apnea (CSA) in patients with heart failure. According to the company, up to